Next-generation CAR T cell therapies for glioblastoma.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 39196960.
- Also identified by DOI 10.1126/scitranslmed.adp2660.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Interim results from two phase 1 trials demonstrate progress in the use of chimeric antigen receptor (CAR) T cell therapy for recurrent glioblastoma (GBM).
Medical subject headings
- Glioblastoma
- Receptors, Chimeric Antigen
- T-Lymphocytes